N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carboxamide | 321532-05-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carboxamide
• CAS: 321532-05-2
• 化学式: C₁₈H₁₄Cl₂N₂O₂
• mdl: MFCD01214442
• 分子量: 361.227
• InChiKey: CWJWQWOKLIZCGY-UHFFFAOYSA-N

物化性质

• 沸点：
  454.3±45.0 °C(Predicted)
• 密度：
  1.357±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carboxamide 、 碘甲烷 在 potassium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 生成 N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-N,5-dimethyl-4-isoxazolecarboxamide
  参考文献：
  名称：

  Discovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists

  摘要：

  A series of 3-aryl-4-isoxazolecarboxamides identified from a high-throughput screening campaign as novel, potent small molecule agonists of the human TGR5 G-protein coupled receptor is described. Subsequent optimization resulted in the rapid identification of potent exemplars 6 and 7 which demonstrated improved GLP-1 secretion in vivo via an intracolonic dose coadministered with glucose challenge in a canine model. These novel TGR5 receptor agonists are potentially useful therapeutics for metabolic disorders such as type II diabetes and its associated complications.

  DOI：

  10.1021/jm901434t
• 作为产物：
  描述：

  3-氯-4-甲基苯胺 、 3-(2-氯苯基)-5-甲基-4-异恶唑甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(3-chloro-4-methylphenyl)-3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carboxamide
  参考文献：
  名称：

  Discovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists

  摘要：

  A series of 3-aryl-4-isoxazolecarboxamides identified from a high-throughput screening campaign as novel, potent small molecule agonists of the human TGR5 G-protein coupled receptor is described. Subsequent optimization resulted in the rapid identification of potent exemplars 6 and 7 which demonstrated improved GLP-1 secretion in vivo via an intracolonic dose coadministered with glucose challenge in a canine model. These novel TGR5 receptor agonists are potentially useful therapeutics for metabolic disorders such as type II diabetes and its associated complications.

  DOI：

  10.1021/jm901434t

文献信息

• Discovery of 3-Aryl-4-isoxazolecarboxamides as TGR5 Receptor Agonists
  作者：Karen A. Evans、Brian W. Budzik、Sean A. Ross、David D. Wisnoski、Jian Jin、Ralph A. Rivero、Mythily Vimal、George R. Szewczyk、Channa Jayawickreme、David L. Moncol、Thomas J. Rimele、Susan L. Armour、Susan P. Weaver、Robert J. Griffin、Sarva M. Tadepalli、Michael R. Jeune、Todd W. Shearer、Zibin B. Chen、Lihong Chen、Donald L. Anderson、J. David Becherer、Maite De Los Frailes、Francisco Javier Colilla

  DOI：10.1021/jm901434t

  日期：2009.12.24

  A series of 3-aryl-4-isoxazolecarboxamides identified from a high-throughput screening campaign as novel, potent small molecule agonists of the human TGR5 G-protein coupled receptor is described. Subsequent optimization resulted in the rapid identification of potent exemplars 6 and 7 which demonstrated improved GLP-1 secretion in vivo via an intracolonic dose coadministered with glucose challenge in a canine model. These novel TGR5 receptor agonists are potentially useful therapeutics for metabolic disorders such as type II diabetes and its associated complications.